Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D. Solomon, Subodh Verma, John J.V. McMurray et al.|New England Journal of Medicine|2024Cited by 693
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trialsJacob A. Udell, Deepak L. Bhatt, Marc S. Sabatine et al.|European Heart Journal|2015Cited by 371
Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care ProvidersAdriana Luk, Michael McDonald, Brian Clarke et al.|Canadian Journal of Cardiology|2021Cited by 66
Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF TrialScott D. Solomon, Dirk von Lewinski, John W. Ostrominski et al.|European Journal of Heart Failure|2024Cited by 62
The risk of death or unplanned readmission after discharge from a COVID-19 hospitalization in Alberta and OntarioFinlay A. McAlister, Douglas S. Lee, Yuan Dong et al.|Canadian Medical Association Journal|2022Cited by 21